ATE290212T1 - Immunologische bestimmungen von prostata- spezifischem antigen - Google Patents

Immunologische bestimmungen von prostata- spezifischem antigen

Info

Publication number
ATE290212T1
ATE290212T1 AT95906713T AT95906713T ATE290212T1 AT E290212 T1 ATE290212 T1 AT E290212T1 AT 95906713 T AT95906713 T AT 95906713T AT 95906713 T AT95906713 T AT 95906713T AT E290212 T1 ATE290212 T1 AT E290212T1
Authority
AT
Austria
Prior art keywords
psa
specific antigen
prostate specific
presented
immunoassay
Prior art date
Application number
AT95906713T
Other languages
English (en)
Inventor
Barry L Dowell
Carol A King
Debra B Alexander
Allan H Smith
Susan B O'morchoe
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of ATE290212T1 publication Critical patent/ATE290212T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95906713T 1993-12-29 1994-12-22 Immunologische bestimmungen von prostata- spezifischem antigen ATE290212T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/174,964 US5599677A (en) 1993-12-29 1993-12-29 Immunoassays for prostate specific antigen
PCT/US1994/014902 WO1995018381A1 (en) 1993-12-29 1994-12-22 Immunoassays for prostate specific antigen

Publications (1)

Publication Number Publication Date
ATE290212T1 true ATE290212T1 (de) 2005-03-15

Family

ID=22638254

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95906713T ATE290212T1 (de) 1993-12-29 1994-12-22 Immunologische bestimmungen von prostata- spezifischem antigen

Country Status (8)

Country Link
US (2) US5599677A (de)
EP (1) EP0741868B1 (de)
JP (2) JP3486413B2 (de)
AT (1) ATE290212T1 (de)
AU (1) AU1518795A (de)
DE (1) DE69434286T2 (de)
ES (1) ES2238678T3 (de)
WO (1) WO1995018381A1 (de)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5723302A (en) * 1993-05-14 1998-03-03 Nordion International Inc. Detection of prostate-specific antigen in breast tumors
US5654161A (en) * 1995-05-12 1997-08-05 Chiron Diagnostics Corporation Method for diagnosing prostate cancer
EP0789032A2 (de) * 1996-02-01 1997-08-13 Bayer Corporation Verfahren zur Herstellung eines monoklonalen Antikörpers, der zu einer equimolären Responz gegen eine freie und komplexierte Analyseprobe in einem monoklonalen/polyklonalen Sandwichimmuntest
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
JP2000514919A (ja) * 1996-07-03 2000-11-07 ミレニアム ファーマシューティカルズ，インコーポレイテッド 少くとも三分枝の連鎖オリゴ糖を持つ癌特異的抗原の検定による癌の検出
DE19641560A1 (de) * 1996-10-09 1998-04-16 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease
IL121659A (en) * 1996-10-25 2000-07-16 Bayer Ag Method for determining CPSA in a blood sample
US5840501A (en) * 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5856182A (en) * 1996-11-18 1999-01-05 Beckman Coulter, Inc. Monoclonal antibodies specific for the PSA-ACT complex
US6548260B1 (en) 1997-01-21 2003-04-15 Bayer Corporation Detection of PSA-α2-macroglobulin complex in a biological fluid
US7288636B2 (en) * 1997-04-30 2007-10-30 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
EP0983509B1 (de) * 1997-05-14 2005-08-17 Biosite Diagnostics Inc. Schnelle bestimmung des verhältnisses von biologischen molekülen
US6780598B1 (en) * 1997-06-13 2004-08-24 William J. Kokolus Method of identifying and locating immunobiologically-active linear peptides
CA2243033A1 (en) * 1997-07-31 1999-01-31 Bayer Corporation Determination of psa-act
US6194152B1 (en) 1997-08-20 2001-02-27 Dendreon Corporation Prostate tumor polynucleotide compositions and methods of detection thereof
US6649420B1 (en) 1997-08-26 2003-11-18 Thomas L. Cantor Methods and devices for detecting no-complexed prostate specific I antigen
US5994085A (en) * 1997-08-26 1999-11-30 Cantor; Thomas L. Methods and devices for detecting non-complexed prostate specific antigen
AU9374198A (en) 1997-09-08 1999-03-29 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
US6300088B1 (en) 1997-11-24 2001-10-09 Duke University Method of detecting prostate specific antigen
US6352834B1 (en) * 1998-07-17 2002-03-05 University Of Iowa Research Foundation Prostate cancer assays and related methods
EP1151142A2 (de) * 1999-01-28 2001-11-07 Gen-Probe Incorporated Nukleinsäure sequenzen für den nachweis von genetischen markern für krebs in einer biologischen probe
CA2370749A1 (en) 1999-04-20 2000-10-26 Target Discovery, Inc. Polypeptide fingerprinting methods, metabolic profiling, and bioinformatics database
DE19957065B4 (de) * 1999-11-26 2005-01-05 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Screening-Verfahren für Arzneistoffe
FR2810114B1 (fr) * 2000-06-13 2002-08-23 Bio Merieux Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
DK1299727T3 (da) 2000-07-12 2009-06-15 Agensys Inc Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
EP1178317B1 (de) 2000-07-24 2004-11-10 Health Research, Inc. Verfahren zur Detektion von Prostata-spezifischem Membran-Antigen in Serum
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6764825B1 (en) * 2000-10-13 2004-07-20 Tang J. Wang Methods and device for detecting prostate specific antigen (PSA)
US6720193B2 (en) * 2001-02-05 2004-04-13 Board Of Regents Of The University Of Nebraska Analysis of free analyte fractions by rapid affinity chromatography
US6500671B2 (en) 2001-02-05 2002-12-31 The Board Of Regents Of The University Of Nebraska Loading microcolums for the separation of analytes from a sample in the millisecond time scale
US6727104B2 (en) 2001-02-05 2004-04-27 The Board Of Regents Of The University Of Nebraska Microcolumn chromatographic immunoassays
EP1383922A4 (de) 2001-04-10 2005-03-30 Agensys Inc Nukleinsäure und zugehöriges, für die behandlung und den nachweis von krebs geeignetes protein mit der bezeichnung 158p3d2
US7811575B2 (en) * 2001-04-10 2010-10-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
EP1390069A1 (de) * 2001-05-30 2004-02-25 Cornell Research Foundation, Inc. Endopeptidase/anti-psma-antikörper-fusionsproteine zur behandlung von krebs
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
EP1427377A4 (de) * 2001-09-20 2006-04-12 Cornell Res Foundation Inc Verfahren und zusammensetzungen zur behandlung oder prävention von hauterkrankungen unter verwendung von bindemitteln, die für das prostataspezifische membranantigen spezifisch sind
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
AU2003201741A1 (en) 2002-01-09 2003-07-24 Yusuke Nakamura Cancer profiles
US7138230B2 (en) 2002-12-06 2006-11-21 Renovar, Inc. Systems and methods for characterizing kidney diseases
US20040018577A1 (en) * 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US20040136998A1 (en) * 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
AU2003296925A1 (en) * 2002-11-01 2004-06-07 Leucadia Technologies, Inc. Displacement sandwich immuno-pcr
ATE408712T1 (de) * 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
US8003765B2 (en) * 2003-04-09 2011-08-23 Stony Brook Anaesthesiology, University Faculty Practice Corporation Methods, antibodies and kits for detecting cerebrospinal fluid in a sample
US20070003992A1 (en) * 2003-04-09 2007-01-04 Pentyala Srinivas N Methods and kits for detecting cerebrospinal fluid in a sample
US20040203079A1 (en) * 2003-04-09 2004-10-14 Research Foundation Of The State University Of New York Methods and kits for detecting cerebrospinal fluid in a sample
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005070456A2 (en) * 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US20050266503A1 (en) * 2004-05-24 2005-12-01 Esoterix, Inc. Simultaneous assay of target and target-drug binding
US20080152700A1 (en) 2004-06-01 2008-06-26 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US7279281B2 (en) * 2004-06-01 2007-10-09 The Regents Of The University Of Michigan Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
DK1842226T3 (da) * 2004-11-03 2010-10-18 Iris Molecular Diagnostics Inc Homogen analytpåvisning
EP2302078B1 (de) * 2004-11-03 2015-07-15 Iris Molecular Diagnostics, Inc. Mikrobläschen zur Konzentration mittels Affinitätstrennung
US7439024B2 (en) * 2005-06-01 2008-10-21 The United States Of America As Represented By The Department Of Veterans Affairs Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2007047907A2 (en) * 2005-10-14 2007-04-26 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
CA2628255C (en) * 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
CA2655340C (en) 2006-06-12 2016-10-25 President And Fellows Of Harvard College Nanosensors and related technologies
US8349604B2 (en) * 2006-06-15 2013-01-08 University Of South Florida Nano-based device for detection of disease biomarkers and other target molecules
US20080100279A1 (en) * 2006-06-15 2008-05-01 University Of South Florida Nano-Based Device for Detection of Disease Biomarkers and Other Target Molecules
US20100136537A1 (en) * 2006-10-10 2010-06-03 The Regents Of The University Of Michigan Photoreceptor precursor cells
US20080125582A1 (en) * 2006-10-13 2008-05-29 Bio-Rad Laboratories, Inc. Methods and compositions for stabilizing prostate specific antigen
WO2008127314A1 (en) 2006-11-22 2008-10-23 President And Fellows Of Harvard College High-sensitivity nanoscale wire sensors
WO2008092002A2 (en) * 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
JP5305361B2 (ja) 2007-05-04 2013-10-02 オプコ・ダイアグノスティクス・リミテッド・ライアビリティ・カンパニー 流体コネクタおよびマイクロ流体システム
EP2515116A1 (de) 2007-05-18 2012-10-24 Duke University Serum-Biomarker für den frühen Nachweis von Lungenkrebs
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
EP2173379B2 (de) 2007-07-02 2023-07-05 Oncomed Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
WO2009021190A2 (en) * 2007-08-08 2009-02-12 Renovar, Inc. Systems and methods for characterizing lupus erythematosus
EP2201134B1 (de) * 2007-09-19 2018-11-21 The Research Foundation of State University of New York Genexpressionssignaturen in angereicherten tumorzellproben
WO2009091556A2 (en) * 2008-01-17 2009-07-23 The General Hospital Corporation Diagnostic methods and kits using fibroblast growth factor-23
CN103884840A (zh) * 2008-02-21 2014-06-25 艾瑞斯国际有限公司 早期确定前列腺癌治疗后复发的方法
US20110092452A1 (en) * 2008-03-05 2011-04-21 The Regents Of The University Of Michigan Compositions and methods for diagnosing and treating pancreatic cancer
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
KR20110093893A (ko) 2008-11-11 2011-08-18 더 리젠츠 오브 더 유니버시티 오브 미시간 항-ｃｘｃｒ１ 조성물 및 방법
US8362318B2 (en) 2008-12-18 2013-01-29 Board Of Trustees Of Michigan State University Enzyme directed oil biosynthesis in microalgae
WO2010078554A1 (en) 2009-01-05 2010-07-08 Bio-Rad Laboratories, Inc. Process design using mass spectrometry
DK2391451T3 (en) 2009-02-02 2018-10-15 Opko Diagnostics Llc STRUCTURES FOR MANAGING LIGHT INTERACTION WITH MICROFLUIDIC DEVICES
US8481698B2 (en) * 2009-03-19 2013-07-09 The President And Fellows Of Harvard College Parallel proximity ligation event analysis
WO2010126670A2 (en) 2009-03-27 2010-11-04 Gojo Industries, Inc. Compositions and methods for screening and using compounds antagonizing spore-surface interactions
US20100272824A1 (en) * 2009-04-16 2010-10-28 The Texas A&M University System Compositions and methods for preventing and monitoring disease
CA2807645C (en) 2009-08-07 2021-09-07 Affinimark Technologies, Inc. Device and methods for the immunological identification of cerebrospinal fluid
EP2470184B1 (de) 2009-08-28 2018-08-01 Bellweather Farms Chemische laktationsinduktion
WO2011038228A1 (en) 2009-09-24 2011-03-31 President And Fellows Of Harvard College Bent nanowires and related probing of species
WO2011082253A2 (en) 2009-12-30 2011-07-07 Board Of Trustees Of Michigan State University A method to produce acetyldiacylglycerols (ac-tags) by expression ofan acetyltransferase gene isolated from euonymus alatus (burning bush)
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US8574832B2 (en) 2010-02-03 2013-11-05 Massachusetts Institute Of Technology Methods for preparing sequencing libraries
US20110237461A1 (en) 2010-03-17 2011-09-29 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9125931B2 (en) 2010-04-06 2015-09-08 Massachusetts Institute Of Technology Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
CN103168118A (zh) 2010-04-06 2013-06-19 麻省理工学院 用减少数量的转录物测量进行的基因表达概况分析
CN102947703A (zh) * 2010-06-17 2013-02-27 皇家飞利浦电子股份有限公司 多表位测定
EP2407242A1 (de) 2010-07-13 2012-01-18 Dublin City University Direkte Klonanalyse und Auswahltechnologie
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
US9352039B2 (en) 2012-02-09 2016-05-31 The Regents Of The University Of Michigan Method of reducing the number of EMT and MET type breast cancer stem cells
MY193914A (en) 2012-03-05 2022-11-01 Oy Arctic Partners Ab Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume
WO2014005076A2 (en) 2012-06-29 2014-01-03 The Regents Of The University Of Michigan Methods and biomarkers for detection of kidney disorders
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
WO2014105910A1 (en) 2012-12-26 2014-07-03 Oncosynergy, Inc. ANTI- INTEGRIN β1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9907833B2 (en) 2013-07-25 2018-03-06 University Of Florida Research Foundation, Incorporated Use of relaxin to treat placental syndromes
US10392629B2 (en) 2014-01-17 2019-08-27 Board Of Trustees Of Michigan State University Increased caloric and nutritional content of plant biomass
WO2015143228A1 (en) 2014-03-19 2015-09-24 The University Of North Carolina At Chapel Hill Bcl6 expression in eutopic endometrium as a marker for endometriosis and subfertility
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
DK3123381T3 (da) 2014-03-28 2023-11-27 Opko Diagnostics Llc Sammensætninger og fremgangsmåder relateret til diagnose af prostatacancer
WO2016048388A1 (en) 2014-09-26 2016-03-31 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
WO2016160545A1 (en) 2015-03-27 2016-10-06 Opko Diagnostics, Llc Prostate antigen standards and uses thereof
JP6578119B2 (ja) * 2015-03-31 2019-09-18 株式会社Ｌｓｉメディエンス 前立腺特異抗原の測定方法及び測定キット
US11474105B2 (en) 2016-03-31 2022-10-18 The University Of North Carolina At Chapel Hill Methods and compositions for SIRT1 expression as a marker for endometriosis and subfertility
WO2018089335A1 (en) 2016-11-09 2018-05-17 North Carolina State University Treatment of allergic diseases with chimeric protein
US12060437B2 (en) 2018-03-23 2024-08-13 North Carolina State University Methods and compositions for antibody to high affinity receptor for IgE

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7602422A (nl) * 1976-03-08 1977-09-12 Leuven Res & Dev Vzw Trombosetest.
US4849353A (en) * 1980-09-30 1989-07-18 Cornell Research Foundation, Inc. Immunocapture of enzyme inhibitor, enzyme complexes and uses thereof
US4689323A (en) * 1983-09-26 1987-08-25 Miles Laboratories, Inc. Covalently bound heparin--antithrombin-III complex
US5026653A (en) * 1985-04-02 1991-06-25 Leeco Diagnostic, Inc. Scavenger antibody mixture and its use for immunometric assay
US4737456A (en) * 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
SE8601645D0 (sv) * 1986-04-11 1986-04-11 Ulf R Nilsson Immunologiskt forfarande
US5114863A (en) * 1986-09-30 1992-05-19 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody
US5223441A (en) * 1986-10-09 1993-06-29 Syntex (U.S.A.) Inc. Receptors for immune complexes
US5187067A (en) * 1986-12-15 1993-02-16 Teijin Limited Immunological determination of free human protein S and C4bp-protein S complex
EP0288793A3 (de) * 1987-04-22 1990-04-25 Abbott Laboratories Vorrichtung und Verfahren für die Ausführung eines festphasen Immunoassays
DE3727238A1 (de) * 1987-08-14 1989-02-23 Henning Berlin Gmbh Immunologisches bestimmungsverfahren zur bestimmung von hapteneigenschaften aufweisenden freien substanzen
SE9002480D0 (sv) * 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
US5324634A (en) * 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer

Also Published As

Publication number Publication date
US5599677A (en) 1997-02-04
JP2004093563A (ja) 2004-03-25
EP0741868A1 (de) 1996-11-13
US5672480A (en) 1997-09-30
WO1995018381A1 (en) 1995-07-06
AU1518795A (en) 1995-07-17
JP3486413B2 (ja) 2004-01-13
DE69434286D1 (de) 2005-04-07
ES2238678T3 (es) 2005-09-01
JPH09508969A (ja) 1997-09-09
JP3833637B2 (ja) 2006-10-18
EP0741868B1 (de) 2005-03-02
DE69434286T2 (de) 2005-12-29

Similar Documents

Publication Publication Date Title
ATE290212T1 (de) Immunologische bestimmungen von prostata- spezifischem antigen
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DK0724456T3 (da) CD40-Antistoffer
ES8706964A1 (es) Un procedimiento para fraccionar anticuerpos de suero.
ATE331952T1 (de) Bestimmung von spezifischem immunglobulin unter verwendung multipler antigene
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
KR850700111A (ko) 종양 및 비루스에 대하여 항-이디오 타입 항체로써 유도되는 면역반응
FI971883A0 (fi) Vasta-aineluokkapesifinen häiriöitä estävä reagenssi
DK0659276T3 (da) Immunoassay til eftervisning af collagen eller collagenfragmenter
DE3854581D1 (de) Antigen sf-25 des darm-adenokarzinoms sowie antikörper, die dieses antigen erkennen.
FI922017A0 (fi) Immunbestaemningar och monoklonala antikroppar foer protrombinaktiveringspeptider och degradations- produkter av dessa.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
AU2911289A (en) Carcinoma-associated antigens, and antibodies which recognize these antigens
CA2054689A1 (en) An immunoassay method for determining the specificity of binding of a monoclonal antibody to an antigen
ATE108907T1 (de) Bestimmungsverfahren, seine verwendung und komponenten.
CA2178504A1 (en) Immunoassays for prostate specific antigen
DE3568639D1 (en) Method for the determination of a substance capable of immunological binding
NO852058L (no) Fremgangsmaate og middel for bestemmelse av atl virus antistoffer.
FI860937A0 (fi) Menetelmä ja reagenssi follikkelia stimuloivan hormonin määrittämiseksi sekä tähän tarkoitukseen sopivat monoklonaaliset vasta-aineet
NO903820D0 (no) Fremgangsmaate for paavisning av analytter.
AU1997897A (en) Nucleic acid-bound polypeptide, method of producing nucleic acid-bound polypeptide, and immunoassay using the polypeptide
KR950016780A (ko) 신규 모노클로날 항체

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0741868

Country of ref document: EP